Cambridge-based ElevateBio was launched last week by three former Alexion Pharmaceuticals and bluebird bio executives, who ...
Alexion Pharmaceuticals (ALXN) is on the list of such stocks currently recommended by our proprietary system. In addition to a favorable Growth Score, it carries a top Zacks Rank. Studies have ...
Pre-Clinical Programs Complement inhibitors (with Alexion Pharmaceuticals) Zealand and Alexion Pharmaceuticals announced in March that they will collaborate on the discovery and development of novel ...
A dozen companies had net profit margins above 30% in the first quarter, 9 of which were pharma firms. Alexion ...
There was good news the last time Alexion Pharmaceuticals (NASDAQ:ALXN) reported its quarterly results. In February, the company announced higher revenue compared to the prior-year period. Adjusted ...
Apr 26, 2019 (Market Exclusive via COMTEX) -- Analyst Ratings For Alexion Pharmaceuticals, Inc. ALXN, -0.38% Today, Raymond James raised its price target on Alexion Pharmaceuticals, Inc. ALXN, -0.38% ...
* SEES FY 2019 GAAP EPS IN RANGE $6.76 TO $7.96 * SEES FY 2019 NON-GAAP EPS IN RANGE $9.25 TO $9.45 * FY2019 EARNINGS PER SHARE VIEW $9.31, REVENUE VIEW $4.75 BILLION -- REFINITIV IBES DATA Source ...
MSN27d
The former CEO of Alexion Pharmaceuticals and chief scientific officer at bluebird bio have raised $150 million to launch a ...
BOSTON (AP) _ Alexion Pharmaceuticals Inc. (ALXN) on Thursday reported first-quarter net income of $587.9 million. On a per-share basis, the Boston-based company said it had profit of $2.61. Earnings, ...